強
強気
強気 · 25%EXOZ
$12.90
シナリオ価格
$4.400
+0.311 (+7.06%)終値時点
Loading chart…
- 高値
- 4.585
- 始値
- 4.190
- 出来高加重平均価格
- 4.37
- 出来高
- 10.79K
- 時価総額
- —
- 安値
- 4.110
- 売買代金
- 47.09K
- EV/EBITDA（TTM）
- 0.00
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
AI分析 of eXoZymes Inc (EXOZ)
買いExozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
バリュエーション指標
eXoZymes Inc（EXOZ）の現在の予想PERは0.00で、5年平均は0.00です。
Alphio AI による EXOZ の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
8.506-24seekingalphaeXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- 8.506-08seekingalpha
eXoZymes Prices Public Offering to Raise $5.33 Million
9.504-07Yahoo FinanceMDB Capital Holdings Earnings Outlook
9.504-01Yahoo FinanceEXoZymes Inc Earnings Report Analysis and Outlook
- 9.503-31seekingalpha
eXoZymes Reports Increased FY Net Loss and Rising Expenses
EXOZ のよくある質問 — Alphio AI が回答
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. It operates in the Healthcare sector.
Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。